In a November 4, 2015 news release, QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) announced the start of commercialization activities for its GeneReader NGS System, the first complete Sample-to-Insight next-generation sequencing (NGS) solution designed for any laboratory to deliver actionable results. With the introduction of the GeneReader NGS System, QIAGEN is offering the world's first truly end-to-end NGS workflow from primary sample to a final report that provides a simpler, more cost-effective way for clinical testing to take advantage of NGS technology and improve outcomes. The first application for the GeneReader NGS System involves QIAGEN's new Actionable Insights Tumor Panel, the first member of the family of GeneRead QIAact Panels powered by QCI®. This novel gene panel targets 12 clinically actionable genes that are often analyzed in most prevalent types of cancer, including breast, ovarian, colorectal, lung, and melanoma. The panel can detect up to 1,250 different genetic mutations in a tumor sample. The most relevant variants - including those that are part of approved drug labels, reimbursement schemes, professional guidelines, and active phase III clinical trials - have been identified and selected using the QIAGEN Knowledge Base, the industry's largest collection of human-curated genomic findings and scientific literature. QIAGEN demonstrated demonstrate this integrated Sample-to-Insight™ workflow at the Association for Molecular Pathology (AMP) 2015 Annual Meeting from November 4-7 in Austin, Texas (http://www.amp.org/meetings/2015/), where commercialization of the GeneReader NGS System will be initiated.
Login Or Register To Read Full Story